3-Hour Virtual Seminar on Master Validation Plan – The Unwritten Requirements
🎤 John E. Lincoln | 📅 Recording Available | 🕒 3 Hour
  |
|
Description:
FDA Warning Letters and recent high-profile recalls indicate major cGMP deficiencies in many companies. One major failing is lack of sufficient or targeted risk-based company-wide V&V planning. Starting with a Master Validation Plan, evaluating its elements against ISO 14971 hazard analysis / risk management, allows development of meaningful product validations. The roles of different V&V protocols.
How to employ equipment / process DQs, IQs, OQs, and PQs, or their equivalents per ASTM E2500, against a background of limited company resources (personnel, budget, time). A matrix simplifies “as-product”, “in-product”, process, and equipment, et al, software V&VT, assuring key FDA requirements are not overlooked.
What is the FDA definition of “risk based” and how is it documented in the V&V test report. Additional recommended supporting systems / documentation. The QMS / CGMP and 21 CFR Part 11 must also be considered.
Areas Covered in the Session :
- Verification or Validation – Recent regulatory expectations
- The Master Validation Plan and its structure
- Product Validation – how it differs from process / equipment V&V
- Process / Equipment / Facility Validation including FDA’s recent guidance
- When and How to use DQ, IQ, OQ, PQ, or their equivalents
- How to use Product Risk Management Tools (per ISO 14971 and ICH Q9)
- The 11 key documents for software validation
- Incorporating 21 CFR Part 11 requirements
- Suggested “test case” formats
- Approximately two 10 minute breaks during the webinar, with Q&A
